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Introduction 53
Airway epithelium is an extremely important barrier to respiratory pathogens. It is also the primary 54 infection target for many respiratory viruses. Elucidating the interactions between respiratory 55 viruses and airway epithelium is fundamental to understanding aspects of their pathogenesis. We Lower airway sampling. Samples were obtained from 10 infants (mean age 0.31 years, range 165 0.06 -1.3 years) with severe RSV disease who were treated in the pediatric intensive care unit of 166 the Royal Belfast Hospital for Sick Children. Samples were direct tracheobronchial aspirates or 167 deeper suction samples following the instillation of 2 mL saline. All sampling was clinically 168 indicated and not performed for research purposes. Fourteen uninfected and otherwise healthy 169 children (mean age 1.7 years, range 1-2.4 years) acted as controls with blind non-bronchoscopic 170 bronchoalveolar lavage samples obtained (after instillation of 10 mL saline) at the time of 171 intubation for an elective surgical procedure (29). All RSV-infected infants were confirmed as 172 having mono-infections using a multiplex virus reverse transcriptase (RT)-PCR strip for 12 173 respiratory viruses, as previously described (30).
174
Statistical analyses. Data obtained in vitro were described as mean [± SEM] and skewed data were 175 log transformed before comparisons were made by Student's paired t-test or by comparing the areas 176 9 under the curves using GraphpadPrism ® 5.0. Data from RSV-infected and control children were 177 compared using a Mann-Whitney t-test using GraphpadPrism ® 5.0. p < 0.05 was considered 178 statistically significant.
179
Ethics. This study was approved by The Office for Research Ethics Committees Northern Ireland 180 (ORECNI). Written informed parental consent was obtained. IFNλ1/IL-29 is the predominant interferon following RSV infection in-vivo and in-vitro. 196 Previous work from us and others reported little or no IFN-α/β secretion following RSV infection 197 of infants or airway epithelial cells in vitro (1, 32) . In contrast, IL-29 was evident following RSV 198 infection of primary airway (nasal) epithelial cells in vitro (2, 15) . To confirm and extend these 199 findings, we determined IFN-α/β, IL-28A and IL-29 concentrations in lower airway samples from 200 infants hospitalized with severe RSV (n=8-10) and uninfected controls (n=11-14). Apart from one 201 RSV-infected individual with low levels of IFNα, no IFN-α/β was detected in lower airway samples 202 from infected infants ( Fig. 2A and B) . In contrast, IL-29 was significantly elevated in lower airway in part, for the RSV-induced antiviral effects. Importantly, when CMRSV was pre-incubated with 220 anti-IL-29 (CMRSV + αIL-29), the ability of CMRSV to abrogate rSeV/eGFP infection was 221 significantly reduced, suggesting an important role for IL-29 in the antiviral effect of CMRSV.
222
IL-29 attenuates rSeV/eGFP replication in WD-PBECs. 223 To confirm that IL-29 has antiviral activities in airway epithelium, WD-PBECs (n=2-3 donors) relative to controls (Fig. 4A, B ). Furthermore, rSeV/eGFP growth kinetics were significantly 230 reduced following pre-treatment with both IL-29 doses (Fig. 4C ), although these reductions, even 231 at the higher dose, were lower than those evident after CMRSV pre-treatment (Fig. 3C ). The data 232 demonstrated that IL-29 has antiviral activities in airway epithelium and may account for some, 233 but not all, of the antiviral activity associated with CMRSV.
234
CMRSV and IL-29 prophylaxis attenuates RSV growth in WD-PBECs. 235 To assess CMRSV antiviral activity against RSV, WD-PBECs cultures (n=2 donors) were mock- compared with rSeV/eGFP (Fig. 5A ). This was also reflected in significantly reduced rA2-eGFP 241 growth kinetics in CMRSV-treated compared to CMCON-treated WD-PBEC cultures (Fig. 5B ).
242
To assess whether IL-29 had prophylactic or therapeutic potential against the clinical isolate RSV 243 BT2a, cultures (n=3 donors) were untreated or treated with IL-29 for 24 h before infection 244 (MOI~0.01) (1 ng/mL or 100 ng/mL), or at 2 or 24 hpi (100 ng/mL). Pre-treatment with 100 ng/mL 245 IL-29 significantly reduced RSV replication (p<0.05), while pre-treatment with 1 ng/mL IL-29 did 246 not (Fig. 5C ). In contrast, IL-29 did not demonstrate therapeutic potential against RSV under our 247 experimental conditions (Fig. 5D ). The cumulative data from Figs. 3 nad 5 suggested that RSV is 248 more resistant to CMRSV and IL-29 than rSeV/eGFP, and that the antiviral activity of CMRSV 249 against RSV in WD-PBECs is similar to that evident following pre-treatment with 100 ng/mL IL-250 29. In view of the considerably lower levels of IL-29 evident in CMRSV than those used in these 251 experiments, IL-29 is unlikely to be solely responsible for the limited spread of RSV in WD-
252
PBECs.
253
RSV NS proteins antagonize IL-29-mediated anti-viral effects. 254 The relative resistance of RSV to IL-29 suggested efficient antagonism of the IFNλ-signaling 255 pathway in WD-PBECs. We and others have shown that RSV NS1 and particularly NS2 are 256 responsible for antagonizing IFN-α/β signaling through degradation of pSTAT2 (19, 33) . However, 257 the capacity of RSV NS1/2 to antagonize IFNλ-mediated innate immune responses is unknown.
258
To determine whether these proteins were implicated in antagonising IL-29-induced responses in Pre-treatment with 1 ng/mL IL-29 had no effect on rA2-eGFP replication, as indicated by eGFP 270 expression kinetics, while 100 ng/mL did (Fig. 7A, C) . By comparison, pre-treatment with either 271 dose of IL-29 had much more dramatic effects on rA2-ΔNS1/2-eGFP replication than rA2-eGFP 272 (Fig. 7B, D) . Thus, RSV NS1/2 proteins are implicated in antagonizing IL-29-mediated antiviral part mediated by IL-29 ( Fig. 8B and C) . We and others previously reported that RSV NS proteins 283 block the IFNα/β-stimulated Jak/STAT signalling pathway by targeting pSTAT2 for proteasomal 284 degradation (19, 37) . To study RSV antagonism of Jak/STAT signalling and MxA/B expression in 285 14 WD-PBECs, cultures (n=3-4 donors) were infected with RSV (MOI~0.1), subjected to daily apical 286 rinses and basolateral medium change, fixed, permeabilized and co-stained for RSV F and either 287 pSTAT1, pSTAT2 or MxA/B at 144 hpi ( Fig. 9A-F ). pSTAT1 fluorescence intensities were similar 288 in both infected and non-infected cells (Fig. 9E, F) . In contrast, pSTAT2 protein was significantly 289 diminished (Fig. 9C, D) , while MxA/B proteins were virtually absent (Fig. 9A, B) , in RSV-infected is that the IFN antagonistic capacities of these viruses likely evolved to cope with IFN-λs, rather 326 than IFN-α/β, responses.
327
Therefore, we evaluated the capacity of RSV NS1/2 to antagonize IFN-λ1/IL-29-mediated antiviral 328 effects. We demonstrated that NS1 and/or NS2 were essential for RSV resistance to IL-29- There is an increasing body of evidence confirming the capacity of IL-29 to induce antiviral states 341 in infected cells (5, 8, 44) . Our data extend this IL-29 capacity to SeV and RSV. We found no 342 evidence that IL-29 has therapeutic potential against RSV infection. However, we present evidence 343 that IL-29 has prophylactic potential against RSV, as demonstrated by retarded RSV growth 344 kinetics in IL-29 pre-treated WD-PBECs compared with untreated controls. These data provide the 345 rationale for further studies on IL-29 prophylaxis to modulate RSV pathogenesis. This is of 346 particular interest for individuals at risk for severe illness due to RSV infection, although more 
360
However, further work is required to identify such molecules and determine whether such synergy 361 is evident in our WD-PBEC model.
362
Finally, there is increasing molecular diagnostic evidence demonstrating concomitant dual or 363 multiple respiratory viral infections in individuals (50, 51) . Debate is ongoing as to whether such 364 dual/multi-infections result in exacerbated disease compared with mono-infections. Extrapolation 365 of our data to the clinic suggests that a primary infection with RSV would result in the induction 366 of an antiviral state in the airway epithelium that may greatly compromise the capacity of 367 subsequent viruses to infect and replicate, unless the second virus was adept at circumventing the 368 pre-established innate immune responses. This is consistent with a recent study showing that 369 infection with multiple respiratory viruses correlated with less severe disease (52).
370
In conclusion, our study significantly advances our understanding of RSV induction and 371 antagonism of type III IFN responses in human airway epithelium. Importantly, it provides the 372 rationale for dissecting the molecular mechanisms by which these occur and the possible 373 exploitation of IL-29 as a novel RSV prophylactic, either alone or in combination with other yet-374 to-be discovered CMRSV antiviral molecules. 
